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Purpose: Recently, point mutations in surface-exposed tyrosine residues have been 
shown to increase AAV transduction significantly. We examined the efficacy of 
conventional AAV8 and next generation tyrosine-mutant AAV8 vectors to deliver 
genes into corneal endothelium in vivo.  
 
Methods: The study, which used female C57BL/6 mice, was approved by the 
institutional animal care and use committee and experiments were performed in 
accordance with the tenets of the ARVO statement for the use of animals. Ketamine 
and Xylazine hydrochloride were administered for anesthesia. Two microliters of 
AAV8 titer (~1010 vg/ml) was injected into the anterior chamber of the eye from four 
different clock-positions with the Hamilton Microinjection Syringe System under an 
operating microscope. Eyes were then washed with water and sponge-dried. Slit lamp 
microscopy was utilized for clinical eye exam. Stereomicroscopy and 
immunocytochemistry techniques measured the levels and location of transgene. 
Delivered-transgene expression was quantified with real-time PCR and western blot 
analyses.          
 
Results: Both, conventional and tyrosine-mutant AAV8 vectors successfully 
transduced mouse corneal endothelium in vivo. Mutant AAV8 showed significantly 
higher transgene delivery into corneal endothelium than the conventional AAV8. 
Injections performed from 12 or 3 o’clock position showed highest targeted transgene 
delivery into corneal endothelium. Low-to-mild transgene delivery was also detected 
in the stroma. The tested AAV8 showed no apparent side effects or toxicity. 
 
Conclusions: Tested AAV8 vectors are efficient to treat corneal endothelial 
dystrophies via gene therapy. Future studies will determine optimal doses of 
conventional and tyrosine-mutant AAV8 vectors to deliver therapeutic genes into 
corneal endothelial in vivo.   
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